马淑芹, 郑全辉, 张庆波, 幺文博, 刘洪梅, 杨雷, 刘丽. 食管癌疫苗抗癌机理研究[J]. 中国肿瘤临床, 2012, 39(24): 2066-2069. DOI: 10.3969/j.issn.1000-8179.2012.24.020
引用本文: 马淑芹, 郑全辉, 张庆波, 幺文博, 刘洪梅, 杨雷, 刘丽. 食管癌疫苗抗癌机理研究[J]. 中国肿瘤临床, 2012, 39(24): 2066-2069. DOI: 10.3969/j.issn.1000-8179.2012.24.020
shu
Shuqin MA, Quanhui ZHENG, Qingbo ZHANG, Wenbo YAO, Hongmei LIU, Lei YANG, Li LIU. Anticancer Mechanism of Esophagus Cancer Vaccine[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(24): 2066-2069. DOI: 10.3969/j.issn.1000-8179.2012.24.020
Citation: Shuqin MA, Quanhui ZHENG, Qingbo ZHANG, Wenbo YAO, Hongmei LIU, Lei YANG, Li LIU. Anticancer Mechanism of Esophagus Cancer Vaccine[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(24): 2066-2069. DOI: 10.3969/j.issn.1000-8179.2012.24.020
shu

食管癌疫苗抗癌机理研究

Anticancer Mechanism of Esophagus Cancer Vaccine

    摘要
  • 摘要:
      目的  对食管癌可溶性抗原和超抗原SEC构建的肿瘤疫苗的抗癌机理进行研究。
      方法  培养食管癌细胞Eca109，提取其抗原成分，和超抗原金葡素SEC构建成肿瘤疫苗；分离人外周血单个核细胞（peripheral blood mononuclear cells, PBMC），经肿瘤疫苗联合作用，进行体外培养，进行增殖，成为效应细胞；流式细胞术（FCM）测定效应细胞表型；细胞毒试验检测其杀伤活性，FCM测定效应细胞诱导靶细胞凋亡情况。
      结果  经肿瘤疫苗刺激的淋巴细胞组增殖活性最强，于72 h达到高峰，并且上调CTLs中CD8+T细胞群。肿瘤疫苗刺激的淋巴细胞组诱导的CTLs对靶细胞杀伤活性显著高于单纯淋巴细胞组（P < 0.01）。经效应细胞作用后，靶细胞的凋亡率为32.44%，而对照组仅6.38%的细胞凋亡，具有统计学差异（P < 0.01））。
      结论  食管癌抗原与超抗原构建的肿瘤疫苗能诱导效应细胞明显增殖、活化、并产生高效、特异的抗肿瘤效果，效应细胞可诱导靶细胞凋亡，从而发挥抗癌作用。

     

    Abstract:
      Objective  This work aims to assess the anticancer mechanism of esophagus cancer vaccine for clinical application.
      Methods  Esophagus cancer cells were cultured, and the soluble antigens were extracted from them. Esophagus cancer vaccine was constructed with the antigen and superantigen SEC. Lymphocytes were isolated from peripheral blood, and then stimulated with the vaccine in vitro. Phenotypes of the cells were checked by FCM, and killing activity was tested with cytotoxic assay. Apoptosis of target cells were induced by effect cells checked with FCM.
      Results  The proliferation of the lymphocyte group stimulated by the vaccine is the strongest, which peaked at 72 h, thus raising CD8+T cell populations of CTLs. The killing activity of the lymphocyte group, which is stimulated by the vaccine against target cells is significantly higher than that of the lymphocyte group (P < 0.01). Apoptosis occurred in 33.44% of the target cells after induction of the effect cells and 6.38% in the control group. There is a significant difference between them (P < 0.01).
      Conclusion  The tumor vaccine constructed with esophagus cancer antigen and superantigen SEC can induce PBMC to activate and proliferate into CD8+CTL, with specific cytotoxicity against the cells from which the antigen comes from. The CTL induced by the vaccine can result in the apoptosis of tumor cells as target cells for the action of anticancer.

     

    • HTML全文
    • 参考文献(12)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回